{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:51:56Z","timestamp":1781614316640,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Denys-Drash syndrome (DDS) is defined by early onset nephrotic syndrome rapidly progressing to end stage renal disease (ESRD) before 4 years of age, male pseudohermaphroditism, and Wilms tumor (WT). DDS is associated with mutations in the\n WT1<\/jats:italic>\n gene, most commonly in exons 8 or 9.\n ACTN4<\/jats:italic>\n mutations are associated with nephrotic syndrome and renal dysfunction, with an onset in early adulthood.\n <\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n \n We present the case of an 18-year-old male with a past medical history of Wilms tumor (status post right nephrectomy, chemotherapy, and radiation during infancy), Denys-Drash syndrome, chronic kidney disease stage 2, and autism spectrum disorder. The patient presented to our clinic with worsening proteinuria discovered secondary to pyelonephritis. Genetic evaluation revealed a\n WT1<\/jats:italic>\n mutation, c.388_389insAC (p.Pro130Hisfs*34), complicated by an\n ACTN4<\/jats:italic>\n mutation, c.2698T\u2009>\u2009A (p.Ser900Thr). Under our care, his worsening proteinuria stabilized, and his estimated glomerular filtration rate (eGFR) remained at 83 mL\/min\/1.73 m\n 2<\/jats:sup>\n (1.38 mL\/s\/1.73 m\n 2<\/jats:sup>\n ), indicating preserved renal function. We used a multidisciplinary approach to manage this patient through lifestyle modification, regular monitoring, and conservative measures. Surveillance with regular ultrasounds and labs has been key in management. We chose to forgo biopsy because of the risk to the remaining kidney, and we will continue to evaluate the need for an angiotensin-converting enzyme (ACE) inhibitor on the basis of hemodynamic stability.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n In this case, we present a patient with delayed nephropathy in the presence of novel\n WT1<\/jats:italic>\n and\n ACTN4<\/jats:italic>\n mutations, suggesting the potential for a new genotype\u2012phenotype relationship of DDS or the attenuation of disease behavior. When diagnostic testing is limited due to increased risk to the patient, we emphasize the need for personalized treatment plans and a multimodal approach with close monitoring in the long-term management of such complicated cases. This case documents novel mutations, highlights the importance of genetic testing, and justifies further investigation into the relationship between genotype and phenotype for patients with mutations contributing to renal pathology.\n <\/jats:p>\n <\/jats:sec>\n \n Clinical trial registration<\/jats:title>\n Not applicable.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12882-025-04433-4","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:44:43Z","timestamp":1756716283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel WT1 and ACTN4 co-mutations in a patient with Denys-Drash syndrome and an atypical, potentially attenuated presentation of nephropathy: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Eric","family":"Frazier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sabour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"11","key":"4433_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00467-006-0208-1","volume":"21","author":"P Niaudet","year":"2006","unstructured":"Niaudet P, Gubler MC. WT1 and glomerular diseases. Pediatr Nephrol. 2006;21(11):1653\u201360. https:\/\/doi.org\/10.1007\/s00467-006-0208-1","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"4433_CR2","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s00467-024-06302-y","volume":"39","author":"M Lopez-Gonzalez","year":"2024","unstructured":"Lopez-Gonzalez M, Ariceta G. WT1-related disorders: more than Denys-Drash syndrome. Pediatr Nephrol. 2024;39(9):2601\u201309. https:\/\/doi.org\/10.1007\/s00467-024-06302-y","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4433_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/ckj\/sfz022","volume":"12","author":"N Roca","year":"2019","unstructured":"Roca N, Mu\u00f1oz M, Cruz A, Vilalta R, Lara E, Ariceta G. Long-term outcome in a case series of Denys-Drash syndrome. Clin Kidney J. 2019;12(6):836\u20139. https:\/\/doi.org\/10.1093\/ckj\/sfz022","journal-title":"Clin Kidney J"},{"key":"4433_CR4","unstructured":"Lipska-Zietkiewicz B (Expert Reviewer). Knowledge on rare diseases and orphan drugs: Denys-Drash syndrome. Orphanet. Last updated Dec 2019. Accessed Aug 2025. https:\/\/www.orpha.net\/en\/disease\/detail\/220?name=denys%20drash%26mode=name#menu"},{"key":"4433_CR5","doi-asserted-by":"publisher","first-page":"847295","DOI":"10.3389\/fped.2022.847295","volume":"10","author":"P Arroyo-Parejo Drayer","year":"2022","unstructured":"Arroyo-Parejo Drayer P, Seeherunvong W, Katsoufis CP, et al. Spectrum of clinical manifestations in children with WT1 mutation: case series and literature review. Front Pediatr. 2022;10:847295. https:\/\/doi.org\/10.3389\/fped.2022.847295","journal-title":"Front Pediatr"},{"key":"4433_CR6","doi-asserted-by":"publisher","unstructured":"Tentler D, Lomert E, Novitskaya K, Barlev NA. Role of ACTN4 in tumorigenesis, metastasis, and EMT. Cells. 2019;8(11). https:\/\/doi.org\/10.3390\/cells8111427","DOI":"10.3390\/cells8111427"},{"key":"4433_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13578-015-0036-8","volume":"5","author":"D Feng","year":"2015","unstructured":"Feng D, DuMontier C, Pollak MR. The role of alpha-actinin-4 in human kidney disease. Cell Biosci. 2015;5:44. https:\/\/doi.org\/10.1186\/s13578-015-0036-8","journal-title":"Cell Biosci"},{"key":"4433_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2490-9-19","volume":"9","author":"B Glodny","year":"2009","unstructured":"Glodny B, Unterholzner V, Taferner B, Hofmann KJ, Rehder P, Strasak A, et al. Normal kidney size and its influencing factors - a 64-slice MDCT study of 1.040 asymptomatic patients. BMC Urol. 2009;9:19. https:\/\/doi.org\/10.1186\/1471-2490-9-19","journal-title":"BMC Urol"},{"issue":"4S","key":"4433_CR9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"4433_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5414\/CNCS109515","volume":"6","author":"L Gari\u00e9py-Assal","year":"2018","unstructured":"Gari\u00e9py-Assal L, Gilbert RD, \u017diaugra A, Foster BJ. Management of Denys-Drash syndrome: A case series based on an international survey. Clin Nephrol Case Stud. 2018;6:36\u201344. https:\/\/doi.org\/10.5414\/CNCS109515","journal-title":"Clin Nephrol Case Stud"},{"issue":"12","key":"4433_CR11","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/s41372-021-01279-0","volume":"41","author":"AS AbuMaziad","year":"2021","unstructured":"AbuMaziad AS, Abusaleh R, Bhati S. Congenital nephrotic syndrome. J Perinatol. 2021;41(12):2704\u201312. https:\/\/doi.org\/10.1038\/s41372-021-01279-0","journal-title":"J Perinatol"},{"issue":"11","key":"4433_CR12","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00467-007-0633-9","volume":"24","author":"H Jalanko","year":"2009","unstructured":"Jalanko H. Congenital nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2121\u20138. https:\/\/doi.org\/10.1007\/s00467-007-0633-9","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"4433_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.ekir.2025.01.014","volume":"10","author":"M Gl\u00e9nisson","year":"2025","unstructured":"Gl\u00e9nisson M, Grapin M, Blanc T, et al. Genotype-Phenotype correlations in Denys-Drash syndrome in children. Kidney Int Rep. 2025;10(4):1205\u201312. https:\/\/doi.org\/10.1016\/j.ekir.2025.01.014","journal-title":"Kidney Int Rep"},{"issue":"14","key":"4433_CR14","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/cncr.29373","volume":"121","author":"RB Interiano","year":"2015","unstructured":"Interiano RB, Delos Santos N, Huang S, et al. Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy. Cancer. 2015;121(14):2449\u201356. https:\/\/doi.org\/10.1002\/cncr.29373","journal-title":"Cancer"},{"key":"4433_CR15","unstructured":"Natera. Renasight Kidney Gene Panel, Final Results Summary. September 11, 2024. Accessed 6 July 2025."},{"issue":"5","key":"4433_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1681\/ASN.2008060613","volume":"20","author":"JM Henderson","year":"2009","unstructured":"Henderson JM, Alexander MP, Pollak MR. Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury. J Am Soc Nephrol. 2009;20(5):961\u20138. https:\/\/doi.org\/10.1681\/ASN.2008060613","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4433_CR17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.34067\/KID.0000812022","volume":"3","author":"C Nagano","year":"2022","unstructured":"Nagano C, Hara S, Yoshikawa N, Takeda A, Gotoh Y, Hamada R, et al. Clinical, pathological, and genetic characteristics in patients with focal segmental glomerulosclerosis. Kidney360. 2022;3(8):1384\u201393. https:\/\/doi.org\/10.34067\/KID.0000812022","journal-title":"Kidney360"},{"issue":"3","key":"4433_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/73456","volume":"24","author":"JM Kaplan","year":"2000","unstructured":"Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause Familial focal segmental glomerulosclerosis. Nat Genet. 2000;24(3):251\u20136. https:\/\/doi.org\/10.1038\/73456","journal-title":"Nat Genet"},{"issue":"6","key":"4433_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/sj.ki.5002751","volume":"73","author":"JM Henderson","year":"2008","unstructured":"Henderson JM, Al-Waheeb S, Weins A, Dandapani SV, Pollak MR. Mice with altered alpha-actinin-4 expression have distinct morphologic patterns of glomerular disease. Kidney Int. 2008;73(6):741\u201350. https:\/\/doi.org\/10.1038\/sj.ki.5002751","journal-title":"Kidney Int"},{"issue":"5","key":"4433_CR20","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1097\/01.asn.0000059864.88610.5e","volume":"14","author":"JL Michaud","year":"2003","unstructured":"Michaud JL, Lemieux LI, Dub\u00e9 M, Vanderhyden BC, Robertson SJ, Kennedy CR. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4. J Am Soc Nephrol. 2003;14(5):1200\u201311. https:\/\/doi.org\/10.1097\/01.asn.0000059864.88610.5e","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4433_CR21","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1097\/01.asn.0000022420.48110.4b","volume":"13","author":"TA Natoli","year":"2002","unstructured":"Natoli TA, Liu J, Eremina V, et al. A mutant form of the wilms\u2019 tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development. J Am Soc Nephrol. 2002;13(8):2058\u201367. https:\/\/doi.org\/10.1097\/01.asn.0000022420.48110.4b","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04433-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:55:58Z","timestamp":1781610958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04433-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4433"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04433-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for reporting individual cases or case series.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for their anonymized information to be published in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.H. serves on the speaker\u2019s bureau of Alexion Pharmaceuticals (Astra-Zeneca rare disease), Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GSK Pharmaceuticals, and Astra-Zeneca proper. He is a consultant for the above and Calliditas Pharmaceuticals. He has worked as a Principal investigator on trials with Otsuka, Alexion, Remegen, Roche, Apellis, Novartis, and Calliditas Pharmaceuticals. E.F., R.S., M.D.N., and D.L. declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}